LINC01170

Across TCGA pan-cancer cohorts, LINC01170 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of LINC01170’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LINC01170 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01170 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

THCA, HNSC, and KIRC are the cancer types where LINC01170 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01170 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	+1.610	<.001	11	view →
HNSC	Male	II,III,IV	−0.412	<.001	8	view →
KIRC	All	II,III,IV	+0.063	.004	6	view →
COAD	All	All	+0.106	.012	4	view →
LIHC	All	All	+0.062	.016	3	view →
CHOL	Male	All	+0.133	.003	2	view →
LUAD	All	III,IV	−0.202	.020	1	view →
LUSC	All	All	−0.136	.015	1	view →
STAD	Female	III,IV	+0.065	.049	1	view →
KICH	Female	III,IV	+0.053	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

LINC01170–THCA

Open the THCA breakdown →